Drug intelligence / Profile preview

SKB394-B

Development stage: Unknown
Lead developer: Kelun-Biotech
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

SKB394-B is an investigational anti-BCMA (B-cell maturation antigen) CAR T-cell therapy developed for the treatment of relapsed or refractory multiple myeloma. This therapy involves engineering a patient's own T cells to express a chimeric antigen receptor (CAR) that specifically targets BCMA, a protein highly expressed on malignant plasma cells in multiple myeloma. By redirecting the immune system to recognize and destroy BCMA-expressing cancer cells, SKB394-B aims to provide a novel therapeutic option for patients who have exhausted standard treatments[1].

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on SKB394-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKB394-B.

Explore the full profile